Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aburaihan versus Merck levothyroxine in newly diagnosed hypothyroidism
IRCT20220307054211N1Phase 2Completed
- Sponsor
- Aburaihan Pharmaceutical Company
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of levothyroxine sodium in hypothyroidism (2 arms), sponsored by Aburaihan Pharmaceutical Company. Primary endpoints: Change in serum TSH, Change in serum FT4 and 2 more. Started Jul 2022; status: completed.
02
Drugs
levothyroxine sodium
03
Conditions
hypothyroidism
Beyond the preview
Go deeper on IRCT20220307054211N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220307054211N1.